SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Preface
0 references·8 citing·32 second hop
Preface (2007)PrefaceBalancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA) (2015)Balancing costs and benefits …War on cancer and the influence of the medical-industrial complex (2013)War on cancer and the influen…The economic pressures for biosimilar drug use in cancer medicine (2012)The economic pressures for bi…International Variability in the Reimbursement of Cancer Drugs by Publically Funded Drug Programs (2012)International Variability in …An Analysis Of Whether Higher Health Care Spending In The United States Versus Europe Is ‘Worth It’ In The Case Of Cancer (2012)An Analysis Of Whether Higher…Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers (2010)Time to market and patient ac…Public funding of new cancer drugs: Is NICE getting nastier? (2009)Public funding of new cancer …Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective (2008)Market and patient access to …Decisions with Multiple Objectives: Preferences and Value Tradeoffs. (1994)Qualitative research in health care: Assessing quality in qualitative research (2000)The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration (2009)Healthcare decision‐making applications using multicriteria decision analysis: A scoping review (2019)Multi-expert multi-criteria decision analysis model to support the conservation of paramount elements in industrial facilities (2022)An International Comparison (2000)Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis (2004)Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs (2009)Cancer economics, policy and politics: What informs the debate? Perspectives from the EU, Canada and US (2014)Estimating The Cost Of New Drug Development: Is It Really $802 Million? (2006)The NICE Cost-Effectiveness Threshold (2008)World Health Report (2013)National Institute for Clinical Excellence and its value judgments (2004)European Perspective on the Costs and Cost-Effectiveness of Cancer Therapies (2007)Health systems in transition. (2010)The New Medical-Industrial Complex (1980)Cancer Wars: How Politics Shapes What We Know and Don't Know about Cancer. (1996)The American Presidency Project (2017)Broadening the scope of our understanding of mechanisms: lessons from the history of the morning-after pill (2019)Fighting Fire or Fighting War: Examining the Framing Effects of COVID-19 Metaphors (2023)Trump’s framing of Covid-19 as a war and conspiracy theories (2023)Is economic evaluation in touch with society's health values? (2004)Orphan drugs and the NHS: should we value rarity? (2005)Value based pricing for NHS drugs: an opportunity not to be missed? (2008)The Burden of Illness of Cancer: Economic Cost and Quality of Life (2001)The Value of a Statistical Life: A Critical Review of Market Estimates Throughout the World (2003)Projections of the Cost of Cancer Care in the United States: 2010-2020 (2011)OECD Factbook 2005: Economic, Environmental and Social Statistics (2005)Health Insurance and Access to Health Care in the United States (2008)Pharmaceutical pricing policies in a global market (2008)Do the Current Performance-Based Schemes in Italy Really Work? “Success Fee”: A Novel Measure for Cost-Containment of Drug Expenditure (2014)Managing Risk and Uncertainty in Health Technology Introduction: The Role of Managed Entry Agreements (2017)
this work references cited by second hop

References

No references inside the corpus for this window.

Cited by

  • 2012The economic pressures for biosimilar drug use in cancer medicine92 cited
  • 2012International Variability in the Reimbursement of Cancer Drugs by Publically Funded Drug Programs89 cited
  • 2015Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA)89 cited
  • 2012An Analysis Of Whether Higher Health Care Spending In The United States Versus Europe Is ‘Worth It’ In The Case Of Cancer73 cited
  • 2010Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers71 cited
  • 2009Public funding of new cancer drugs: Is NICE getting nastier?68 cited
  • 2008Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective67 cited
  • 2013War on cancer and the influence of the medical-industrial complex36 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work